ZNF410 Antibody

What is ZNF410 and what is its significance in research?

ZNF410, also known as APA-1, is a pentadactyl DNA-binding protein containing five tandem canonical C2H2-type zinc fingers. It functions as a transcription factor with the remarkable characteristic of directly activating only a single gene in human erythroid cells—the NuRD component CHD4 . This unique specificity makes ZNF410 distinct from typical metazoan transcription factors that regulate numerous genes. ZNF410 is widely expressed across human tissues but is particularly abundant in the erythroid lineage, with similar expression levels in both fetal and adult erythroblasts . Its significance in research stems from its identified role as a repressor of fetal hemoglobin (HbF), making it a potential therapeutic target for β-hemoglobinopathies such as sickle cell disease .

What applications have been validated for ZNF410 antibodies?

ZNF410 antibodies have been validated for multiple research applications according to published literature. Western blot (WB) applications have been confirmed in at least seven publications, with positive detection in multiple cell lines including HEK-293, MCF-7, HeLa, and U2OS cells, as well as mouse brain tissue . Chromatin immunoprecipitation (ChIP) has been validated in at least one publication, which is particularly significant given ZNF410's role as a DNA-binding transcription factor . The antibody has also been confirmed for use in ELISA applications. Additionally, ZNF410 antibodies have been used to validate knockdown/knockout experiments, as referenced in at least one publication . These validated applications make ZNF410 antibodies versatile tools for investigating this protein's unique biological functions.

What species reactivity has been confirmed for ZNF410 antibodies?

Commercial ZNF410 antibodies, such as the 14529-1-AP clone, have been tested and confirmed to show reactivity with human, mouse, and rat samples . The antibody was generated using a ZNF410 fusion protein (Ag6028) as the immunogen, which may contribute to its cross-species reactivity due to the high conservation of ZNF410 across mammalian species . In published literature, the antibody has been specifically cited for use with human and mouse samples . This cross-species reactivity is particularly valuable for comparative studies and for validating findings across different model systems, allowing researchers to investigate the conserved functions of ZNF410 across species.

How does ZNF410 regulate gene expression in erythroid cells?

ZNF410 employs a unique regulatory mechanism unlike conventional transcription factors. Through CRISPR-Cas9 genetic screening and subsequent validation, researchers determined that ZNF410 functions as a robust repressor of HbF by singularly controlling CHD4 expression . Rather than binding directly to γ-globin genes, ZNF410's chromatin occupancy is exclusively concentrated at two dense binding site clusters in the CHD4 gene, containing a combined 27 ZNF410 binding motifs—an unparalleled genomic arrangement not found elsewhere in the genome . These two regulatory elements completely account for ZNF410's effects on fetal globin repression . Dense mutagenesis studies revealed that the cluster of five C2H2 zinc fingers encoded by exons 6-9 of ZNF410 is critical for its function, suggesting that DNA-binding is essential for its regulatory role . This represents a case of transcriptional cascade regulation, where ZNF410 activates CHD4, which subsequently functions as part of the nucleosome remodeling and deacetylase (NuRD) complex to silence γ-globin expression.

What is the significance of ZNF410's interaction with CHD4 in hemoglobin regulation?

The relationship between ZNF410 and CHD4 represents a crucial link in fetal hemoglobin regulation. CHD4, a component of the NuRD complex, is a known repressor of γ-globin expression . ZNF410's sole direct target in erythroid cells is CHD4, which it activates via binding to two regulatory elements containing densely clustered binding sites . Knockout of ZNF410 reduces CHD4 expression by approximately 60%, a reduction sufficient to substantially de-repress HbF while avoiding cellular or organismal toxicity . This partial reduction appears to hit a "sweet spot" where γ-globin repression is relieved without compromising essential cellular functions that depend on CHD4 . Gene expression profiling has shown that changes following ZNF410 loss mirror the effects of partial CHD4 inhibition . This selective and partial effect on CHD4 makes ZNF410 an attractive therapeutic target for β-hemoglobinopathies, as it offers a potential way to induce HbF with a favorable therapeutic index—providing clinical benefit while minimizing on-target toxicities that might arise from complete CHD4 inhibition.

How should ChIP experiments be optimized when using ZNF410 antibodies?

For optimal Chromatin Immunoprecipitation (ChIP) experiments with ZNF410 antibodies, researchers should consider several key methodological approaches. Based on published research, CUT&RUN (Cleavage Under Targets and Release Using Nuclease) has been successfully employed as an alternative to traditional ChIP for studying ZNF410-DNA interactions . This technique offers advantages for studying ZNF410 as it allows examination of protein-DNA interactions in situ without fragmentation or cross-linking, potentially preserving the integrity of the highly specific binding patterns . When designing ChIP experiments, researchers should focus on the known binding regions of ZNF410, particularly the two regulatory elements of CHD4 containing the 27 combined ZNF410 binding motifs . Positive controls should include primers targeting these known binding regions, while negative controls should include regions not expected to bind ZNF410. Given ZNF410's highly restricted chromatin occupancy, ChIP-seq analysis should be performed with high sequencing depth and stringent peak calling parameters to accurately identify the limited binding sites. Additionally, validation of ChIP results through independent methods such as DNA footprinting or EMSA is recommended to confirm the specificity of ZNF410-DNA interactions.

What is known about ZNF410's chromatin occupancy patterns?

ZNF410 exhibits an extraordinarily restricted chromatin occupancy pattern that distinguishes it from conventional transcription factors. While typical DNA-binding transcription factors bind and directly control thousands of genomic targets, ZNF410's chromatin occupancy is concentrated almost exclusively at the CHD4 locus . Specifically, ZNF410 binds to two dense clusters of binding sites near the CHD4 gene that contain a combined 27 ZNF410 binding motifs—an unparalleled genomic arrangement not found elsewhere in the genome . This highly selective binding pattern explains ZNF410's singular devotion to regulating CHD4 as its sole direct target in erythroid cells . The specificity is conveyed by these evolutionarily conserved clusters of ZNF410 binding sites . DNA binding studies and crystallographic analysis have revealed the precise mode of ZNF410 interaction with DNA . This remarkable specificity makes ZNF410 unique among mammalian transcription factors and represents a special class of gene regulator with singular devotion to regulation of a chromatin subcomplex .

How can ZNF410 antibodies be used to study fetal hemoglobin repression mechanisms?

ZNF410 antibodies provide valuable tools for investigating the mechanisms of fetal hemoglobin repression through several experimental approaches. First, they can be used in ChIP or CUT&RUN experiments to precisely map ZNF410's binding to the regulatory elements of CHD4, revealing the molecular basis for this unique transcriptional relationship . Second, western blot analysis with ZNF410 antibodies can quantify protein levels in various experimental conditions, such as after genetic manipulation (CRISPR-Cas9 editing) or drug treatments aimed at modulating the ZNF410-CHD4-HbF axis . Third, these antibodies enable validation of ZNF410 knockout or knockdown efficiency in cellular and animal models used to study HbF regulation . Researchers can employ immunofluorescence staining to examine ZNF410 localization within erythroid precursors at different developmental stages, potentially revealing temporal regulation patterns. Additionally, co-immunoprecipitation experiments using ZNF410 antibodies might identify potential protein partners that could modulate its function in the context of globin gene regulation. Given that ZNF410 represents a unique type of transcription factor with singular target specificity, antibodies against it are essential for dissecting this distinctive regulatory mechanism that impacts γ-globin silencing.

How should samples be prepared to maximize ZNF410 detection?

To maximize ZNF410 detection in experimental samples, several key preparation steps should be followed. First, select appropriate positive control samples such as HEK-293, MCF-7, HeLa, or U2OS cells, which have been confirmed to express detectable levels of ZNF410 . For tissue samples, mouse brain tissue has shown good reactivity . When preparing cell lysates, use a lysis buffer containing strong detergents (such as RIPA buffer) supplemented with protease inhibitor cocktail to prevent protein degradation. Sonication of samples can help ensure complete lysis and improve protein extraction. For optimal protein denaturation, heat samples at 95°C for 5 minutes in Laemmli buffer containing SDS and DTT or β-mercaptoethanol. Load adequate protein amounts (typically 20-50 μg of total protein per lane) to ensure detection of less abundant proteins. For immunoprecipitation experiments, use at least 500 μg of total protein and 2-5 μg of antibody. When working with tissue samples, homogenization should be thorough, and samples should be clarified by centrifugation to remove debris. For erythroid cells specifically, consider the differentiation stage, as ZNF410 expression levels may vary during erythropoiesis, though it has been reported to be similar in both fetal and adult erythroblasts .

What controls should be included when validating ZNF410 knockdown/knockout experiments?

When validating ZNF410 knockdown/knockout experiments, several critical controls should be included to ensure experimental rigor. First, include mock-treated controls that undergo the same experimental procedures but without the active knockdown/knockout reagent to account for non-specific effects of the manipulation process . Second, employ control sgRNA or shRNA targeting irrelevant loci (such as AAVS1 or GFP) to distinguish specific effects of ZNF410 loss from general CRISPR or RNAi effects . Third, verify knockdown/knockout efficiency at both mRNA (RT-qPCR) and protein (Western blot) levels using validated ZNF410 antibodies . Fourth, include phenotypic readouts known to be affected by ZNF410 depletion, such as HbF levels measured by flow cytometry, RT-qPCR of HBG1/2, and HPLC analysis . Fifth, perform rescue experiments by re-expressing ZNF410 in knockout cells to confirm the phenotype is directly caused by ZNF410 loss . Finally, measure CHD4 expression levels, as CHD4 is the direct target of ZNF410 and should show approximately 60% reduction upon efficient ZNF410 knockout . For in vivo studies, appropriate controls including littermates and isogenic controls should be used, with validation of editing efficiency in relevant tissues and cell populations .

What are the potential cross-reactivity concerns with ZNF410 antibodies?

When using ZNF410 antibodies, researchers should be aware of potential cross-reactivity concerns that could affect experimental interpretation. ZNF410 contains five C2H2-type zinc fingers, a motif found in numerous other zinc finger proteins in the genome . This structural similarity creates potential for cross-reactivity with related proteins, particularly other members of the zinc finger protein family. To address this concern, several validation approaches should be implemented. First, include ZNF410 knockout or knockdown samples as negative controls to confirm antibody specificity . Second, perform peptide competition assays where the antibody is pre-incubated with the immunizing peptide to block specific binding. Third, verify results using multiple antibodies targeting different epitopes of ZNF410 when possible. Fourth, employ immunoprecipitation followed by mass spectrometry to identify all proteins recognized by the antibody. When interpreting Western blot results, carefully evaluate all bands observed, not just those at the expected molecular weight (52-67 kDa) . For ChIP experiments, include IgG controls and validate enrichment at known ZNF410 binding sites versus random genomic regions. Additionally, sequence context analysis of ChIP-seq peaks can help distinguish true ZNF410 binding sites from potential cross-reactive signals.

How can researchers distinguish between potential isoforms of ZNF410?

Distinguishing between potential isoforms of ZNF410 requires a multi-faceted approach combining molecular and immunological techniques. First, researchers should conduct comprehensive bioinformatic analysis of ZNF410 gene structure and transcript variants reported in databases such as Ensembl, NCBI, and UniProt to identify potential alternative splicing events or transcription start sites. Second, RT-PCR analysis using primers spanning exon junctions can detect specific splice variants, which can be followed by sequencing for confirmation. Third, when performing Western blot analysis, use gradient gels (4-20%) to achieve better separation of closely migrating isoforms, and note that ZNF410 has been observed to appear between 52-67 kDa, which could reflect either post-translational modifications or different isoforms . Fourth, utilize antibodies targeting different epitopes of ZNF410 to determine if certain forms lack specific regions. For definitive isoform identification, immunoprecipitation followed by mass spectrometry analysis can provide detailed protein characterization. Additionally, isoform-specific knockdown using siRNAs targeting unique exons can help determine the functional contribution of each variant. When interpreting results from different cell types or tissues, consider that isoform expression may vary with developmental stage, cell type, or physiological condition.

How might targeting ZNF410 be relevant for β-hemoglobinopathy therapeutics?

Targeting ZNF410 presents a promising therapeutic strategy for β-hemoglobinopathies like sickle cell disease and β-thalassemia due to several advantageous characteristics. First, ZNF410 knockout induces significant HbF levels (from about 5.5% to 21.1% in primary erythroblasts) without compromising erythroid maturation or viability, making it an effective target for HbF induction . Second, ZNF410 acts through partial reduction of CHD4 (approximately 60%), which is sufficient to de-repress HbF while avoiding the cellular toxicity that might result from complete CHD4 inhibition . This creates a wide therapeutic index—the gap between effective and toxic doses. Third, preclinical evidence shows that ZNF410/Zfp410 knockout is well-tolerated throughout erythropoiesis, hematopoiesis, and mammalian development . Xenotransplantation studies demonstrated that ZNF410-edited human HSPCs maintained normal multilineage hematopoietic reconstitution while exhibiting elevated HbF levels (approximately 17%) . Fourth, ZNF410 represents a unique therapeutic target as it controls a single direct target gene (CHD4), potentially minimizing off-target effects . Though traditionally transcription factors were considered "undruggable," recent advances in developing small molecules that bind and degrade zinc finger proteins (as with IKZF1) suggest potential approaches for ZNF410 modulation .

What are the implications of ZNF410's singular devotion to CHD4 regulation?

The discovery that ZNF410 exhibits singular devotion to CHD4 regulation represents a paradigm shift in our understanding of transcription factor functionality. This unique regulatory relationship has several significant implications. First, it establishes a new conceptual class of transcription factors that, unlike conventional factors regulating thousands of targets, display extreme target specificity . This challenges the traditional view of transcription factors as broad regulators and suggests evolutionary pressure can create highly specialized regulatory relationships. Second, this singular relationship creates a precise control point in gene regulatory networks, allowing for targeted intervention with potentially fewer off-target effects . Third, the partial reduction of CHD4 (approximately 60%) achieved through ZNF410 knockout appears sufficient to de-repress HbF while maintaining essential cellular functions, revealing an exploitable therapeutic window . Fourth, the remarkable conservation of ZNF410 binding site clusters at the CHD4 locus suggests strong evolutionary pressure to maintain this specific regulatory mechanism . Finally, this discovery illustrates a hierarchical regulation strategy where targeting an upstream factor (ZNF410) can modulate the dosage of a downstream effector (CHD4) more precisely than direct targeting, potentially offering advantages for therapeutic applications in hemoglobinopathies and possibly other disorders involving CHD4-dependent processes .

What phenotypes are observed in ZNF410/Zfp410 knockout models?

ZNF410/Zfp410 knockout models exhibit several notable phenotypes with significant implications for both basic biology and therapeutic applications. In human HUDEP-2 cell models, ZNF410 knockout results in substantial induction of HbF, as measured by increased HbF-positive cells by flow cytometry, elevated HBG1/2 expression by RT-qPCR, and increased HbF by HPLC analysis . These cells show a slight non-significant trend toward increased embryonic HBE1 expression and modest decreases in adult HBB and HBA1/2 expression . Importantly, ZNF410 knockout cells maintain normal growth and viability comparable to controls . In primary human erythroid precursors, ZNF410 knockout similarly induces HbF from approximately 5.5% to 21.1% while preserving normal erythroid maturation based on immunophenotype and enucleation capacity . At the molecular level, ZNF410 knockout reduces CHD4 expression by approximately 60% . In vivo studies with Zfp410 mutant mice demonstrate that these animals survive to adulthood, suggesting minimal developmental impact . Human ZNF410 knockout HSPCs xenotransplanted into immunodeficient mice show normal hematopoietic engraftment and multilineage reconstitution, including B-lymphocyte, T-lymphocyte, granulocyte, monocyte, HSPC, and erythroid contributions, while maintaining elevated HbF levels (approximately 17%) .

How does ZNF410 differ from conventional transcription factors?

ZNF410 represents an extraordinary departure from conventional transcription factor functionality in several fundamental ways. First and most strikingly, while typical transcription factors regulate hundreds or thousands of genes, ZNF410 directly activates only a single gene—CHD4—in erythroid cells . This extreme target specificity is unprecedented among mammalian transcription factors studied to date. Second, the mechanism of this specificity is equally unique: ZNF410 binds to two dense clusters containing a combined 27 binding motifs near the CHD4 gene, a genomic arrangement not found elsewhere in the genome . Third, unlike many transcription factors that bind directly to their effector genes, ZNF410 influences γ-globin expression indirectly through its regulation of CHD4, which then acts as part of the NuRD complex to silence γ-globin . Fourth, ZNF410 appears dispensable for broad cellular functions despite being highly conserved, as knockout models show minimal developmental or physiological disruption beyond HbF derepression . Finally, ZNF410 represents a special form of gene regulator with "singular devotion" to a chromatin subcomplex, establishing a new conceptual class of transcription factors with extreme target specificity . This unique regulatory relationship challenges traditional models of transcriptional control and reveals specialized evolutionary adaptations in gene regulatory networks.